BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Memento EPFL// BEGIN:VEVENT SUMMARY:Advances in Antiviral Vaccine Development DTSTART:20170911T121500 DTEND:20170911T131500 DTSTAMP:20261002T014554Z UID:8a2083b7e78b691bb0dada5947a7fd0e8dca902f9ece5414eecffe85 CATEGORIES:Conferences - Seminars DESCRIPTION:Prof. Barney S. Graham\, NIH\, Bethesda\, MD (USA)\nDISTINGUIS HED LECTURE IN BIOLOGICAL ENGINEERING\n(sandwiches served)\n\nAbstract:\nA ntiviral vaccines have been the most successful biomedical intervention fo r preventing epidemic viral disease. Vaccination for smallpox in humans an d rinderpest in cattle was the basis for disease eradication\, and recent progress in polio eradication is promising. Although early vaccines were d eveloped empirically by passage in live animals or eggs\, more recent vacc ines have been developed because of the advent of new technologies\, parti cularly cell culture and molecular biology. Recent technological advances in gene delivery and expression\, nanoparticles\, protein manufacturing\, and adjuvants have created the potential for new vaccine platforms that ma y provide solutions for vaccines against viral pathogens for which no inte rventions currently exist. In addition\, the technological convergence of human monoclonal antibody isolation\, structural biology\, and high-throug hput sequencing is providing new opportunities for atomic-level immunogen design. Selection of human monoclonal antibodies can identify immunodomina nt antigenic sites associated with neutralization and provide reagents for stabilizing and solving the structure of viral surface proteins. Understa nding the structural basis for neutralization can guide selection of vacci ne targets. Deep sequencing of the antibody repertoire and defining the on togeny of the desired antibody responses can reveal the junctional recombi nation and somatic mutation requirements for B-cell recognition and affini ty maturation. Collectively\, this information will provide new strategic approaches for selecting vaccine antigens\, formulations\, and regimens. M oreover\, it creates the potential for rational vaccine design and establi shing a catalogue of vaccine technology platforms that would be effective against any given family or class of viral pathogens and improve our readi ness to address new emerging viral threats.\n\nBio:\nDr. Graham is an immu nologist\, virologist\, and clinical trials physician whose primary intere sts are viral pathogenesis\, immunity\, and vaccine development. His work is focused on HIV\, respiratory syncytial virus (RSV)\, and emerging viral diseases. He has been involved in the clinical evaluation of candidate HI V vaccines for more than 25 years and has an ongoing interest in science e ducation and expanding research opportunities for African-Americans and ot her under-represented minorities. After graduating magna cum laude from Ri ce University\, he obtained his M.D. from the University of Kansas School of Medicine in 1979. He then completed residency and two chief residencies in internal medicine\, a fellowship in infectious diseases\, and a Ph.D. in microbiology and immunology at Vanderbilt University School of Medicine \, where he rose to the rank of professor of medicine with a joint appoint ment in the department of microbiology and immunology. In 2000\, he became one of the founding investigators for the NIAID Vaccine Research Center\, where he is chief of the Viral Pathogenesis Laboratory and Clinical Trial s Core. He is a member of the American Society for Clinical Investigation and the American Association of Physicians and a fellow of the Infectious Disease Society of America and the American Academy of Microbiology. He ha s served on editorial boards for the Journal of Biological Chemistry\, Jou rnal of Virology\, Journal of Infectious Diseases\, and Journal of AIDS an d is a member of scientific advisory boards for organizations involved in HIV\, RSV\, malaria\, and TB vaccine development.\n  LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 STATUS:CONFIRMED END:VEVENT END:VCALENDAR